Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience-Reference-Cited by-同舟云学术

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Published:2017-02-20 Issue:1 Volume:36 Page:174-181
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Angelopoulou Maria K.¹,Vassilakopoulos Theodoros P.¹,Batsis Ioannis²,Sakellari Ioanna²,Gkirkas Konstantinos³,Pappa Vasiliki³,Giannoulia Panagiota⁴,Apostolidis Ioannis⁴,Apostolopoulos Christos⁵,Roussou Paraskevi⁵,Panayiotidis Panayiotis⁶,Dimou Maria⁶,Kyrtsonis Marie-Christine⁶,Palassopoulou Maria⁷,Vassilopoulos Georgios⁷,Moschogiannis Maria⁸,Kalpadakis Christina⁹,Margaritis Dimitrios¹⁰,Spyridonidis Alexander¹¹,Michalis Eurydiki¹²,Anargyrou Konstantinos¹³,Repousis Panagiotis¹⁴,Hatzimichael Eleutheria¹⁵,Bousiou Zoi²,Poulakidas Elias¹⁶,Grentzelias Dimitrios¹⁷,Harhalakis Nikolaos⁴,Pangalis Gerassimos A.¹⁰,Anagnostopoulos Achilles²,Tsirigotis Panagiotis³

Affiliation:

1. Department of Hematology, Laikon General Hospital; National and Kapodistrian University of Athens; Athens Greece

2. Hematology and Bone Marrow Transplantation Department; General Hospital of Thessaloniki Papanikolaou; Thessaloniki Greece

3. 2nd Department of Internal Medicine, Faculty of Medicine, ATTIKON General University Hospital; National and Kapodistrian University of Athens, Medical School; Athens Greece

4. Department of Hematology; Evaggelismos General Hospital; Athens Greece

5. Third Department of Medicine, “Sotiria” General Hospital of Thoracic Diseases, Hematology Unit; National and Kapodistrian University of Athens, Medical School; Athens Greece

6. 1st Department of Propedeutic Internal Medicine, Laikon General Hospital; National and Kapodistrian University of Athens, Medical School; Athens Greece

7. Department of Hematology, Larissa University Hospital; University of Thessalia; Larissa Greece

8. Department of Hematology; Athens Medical Center; Athens Greece

9. Department of Hematology, Heraklion University Hospital; University of Crete; Heraklion Greece

10. Department of Hematology; Democritus University of Thrace Medical School; Alexandroupolis Greece

11. Bone Marrow Transplantation Unit; University of Patras; Patras Greece

12. Department of Clinical Hematology; “G.Gennimatas” Athens General Hospital; Athens Greece

13. Department of Hematology; Air Force Hospital; Athens Greece

14. Department of Hematology; Metaxa Hospital; Pireaus Greece

15. Department of Hematology, Ioannina University Hospital; University of Ioannina; Ioannina Greece

16. Department of Hematology; 401 Military Hospital of Athens; Athens Greece

17. Hygeia General Hospital; Athens Greece

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference27 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy;Vassilakopoulos;Eur J Haematol,2002

4. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group;Josting;J Clin Oncol,2001

5. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group;Sureda;Clin Oncol,2001

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy;Critical Reviews in Oncology/Hematology;2023-02

2. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers;Frontiers in Immunology;2022-10-11

3. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series;Tumori Journal;2022-04-20

4. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis;Leukemia & Lymphoma;2021-07-29

5. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies;Therapeutic Advances in Hematology;2020-01